The Zacks Investment Research Downgrades Enanta Pharmaceuticals Inc. (ENTA) to Hold

The Zacks Investment Research Downgrades Enanta Pharmaceuticals Inc. (ENTA) to Hold

Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “

Separately, JPMorgan Chase & Co. set a $26.00 price target on Enanta Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 9th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $27.24.

Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) opened at 24.86 on Tuesday. Enanta Pharmaceuticals has a 12-month low of $16.75 and a 12-month high of $41.77. The firm has a 50-day moving average price of $24.56 and a 200-day moving average price of $24.87. The firm has a market cap of $473.21 million, a price-to-earnings ratio of 16.44 and a beta of 0.52.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, August 8th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.03. The company had revenue of $14 million for the quarter, compared to analyst estimates of $13.07 million. Enanta Pharmaceuticals had a return on equity of 11.31% and a net margin of 32.59%. The company’s quarterly revenue was up 20.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.13 earnings per share. Equities research analysts anticipate that Enanta Pharmaceuticals will post $1.02 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. raised its stake in Enanta Pharmaceuticals by 295.7% in the second quarter. BlackRock Inc. now owns 4,614 shares of the company’s stock valued at $102,000 after buying an additional 3,448 shares during the last quarter. Adams Diversified Equity Fund Inc. acquired a new stake in Enanta Pharmaceuticals during the second quarter valued at about $194,000. BlackRock Group LTD raised its stake in Enanta Pharmaceuticals by 7.9% in the second quarter. BlackRock Group LTD now owns 12,038 shares of the company’s stock valued at $265,000 after buying an additional 882 shares in the last quarter. Pacad Investment Ltd. raised its stake in Enanta Pharmaceuticals by 15.3% in the first quarter. Pacad Investment Ltd. now owns 9,800 shares of the company’s stock valued at $288,000 after buying an additional 1,300 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its stake in Enanta Pharmaceuticals by 57.1% in the second quarter. PNC Financial Services Group Inc. now owns 14,042 shares of the company’s stock valued at $310,000 after buying an additional 5,103 shares in the last quarter. Institutional investors and hedge funds own 70.82% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).

Related posts

Leave a Comment